Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

Official Title

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-centre, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

Summary:

This is a Phase III, randomized, placebo-controlled, double-blind, multi-centre study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

Trial Description

Primary Outcome:

  • Progression-Free Survival (PFS) assessed by BICR according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLC
Secondary Outcome:
  • Progression-Free Survival (PFS) assessed by BICR per RECIST 1.1 in all randomised patients with Stage I/II NSCLC
  • Overall Survival (OS)
  • Lung cancer-specific mortality
  • Peak Plasma Concentration (Cmax)
  • Detection of ADA neutralising antibodies titers
  • Health-related quality of life in patients treated with durvalumab monotherapy compared to placebo using the EORTC QLQ-C30
  • Proportion of patients alive and progression free at 24 months from randomisation (PFS24) assessed by BICR according to RECIST 1.1
  • Time to progression (TTP) assessed by BICR according to RECIST 1.1
  • Time to death or distant metastasis (TTDM) assessed by BICR according to RECIST 1.1
  • Time from randomisation to second progression (PFS2) as defined by local standard clinical practice
  • Trough Concentration (Ctrough)
  • Assessment of AEs by CTCAE v 5.0 as measures of the safety and tolerability of durvalumab compared to placebo after administration of SBRT
Patients who complete definitive treatment with SoC SBRT and are confirmed to meet all eligibility criteria will be randomized 1:1 to durvalumab or placebo. The primary objective of this study is to assess the efficacy of durvalumab monotherapy compared to placebo in terms of PFS. Key secondary is to assess the efficacy of Durvalumab monotherapy compared to placebo in terms of OS.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society